41 not yet recruiting. 41 Phase 2, 5 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 41 | Not yet recruiting 41 |
| Phase 1 | 5 | Not yet recruiting 5 |
| Phase 3 | 4 | Not yet recruiting 4 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis EC-18, Placebo EC-18 - Atopic Dermatitis | Phase 2 | Not yet recruiting | Enzychem Lifesciences Corporation | 150 | 2027-05-01 | 2026-08-28 |
| Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) linvemastat, Placebo - Asthma (Diagnosis), Pulmonary Function | Phase 2 | Not yet recruiting | Foresee Pharmaceuticals Co., Ltd. | 135 | 2027-03-01 | 2026-07-20 |
| UNC Cashew Sublingual Immunotherapy Cashew sublingual immunotherapy, Placebo sublingual immunotherapy - Cashew Nut Allergy, Tree Nut Allergies | Phase 2 | Not yet recruiting | University of North Carolina, Chapel Hill | 45 | 2027-03-01 | 2026-10-20 |
| Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome | Phase 2 | Not yet recruiting | University Hospital, Lille | 96 | 2027-01-06 | 2026-05-15 |
| Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) Slow Release DHEA, Placebo - Asthma | Phase 2 | Not yet recruiting | Indiana University | 30 | 2027-01-01 | 2026-02-27 |
| Nebulized Ketamine for Severe Asthma Attacks in Children Ketamine (1 mg/kg), Placebo - Asthma Acute, Exacerbation of Allergic Asthma | Phase 2 | Not yet recruiting | Sultan Qaboos University | 60 | 2027-01-01 | 2026-07-27 |
| LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH) Placebo, LAM-001 - Sarcoidosis Associated Pulmonary Hypertension | Phase 2 | Not yet recruiting | IRulya Therapeutics Inc. | 60 | 2026-12-01 | 2026-10-21 |
| A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) Tulisokibart, Placebo, Background prednisone therapy - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 158 | 2026-11-06 | 2026-10-09 |
| Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis Prednisone, Compound betamethasone - Sarcoidosis, Pulmonary | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 126 | 2026-11-01 | 2026-10-15 |
| Ginger's Therapeutic Potential in Asthma Ginger Extract, Placebo - Asthma | Phase 2 | Not yet recruiting | Emily DiMango, MD | 32 | 2026-11-01 | 2026-08-28 |
| An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations XTMAB-16, Placebo - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Xentria, Inc. | 182 | 2026-10-30 | 2026-10-21 |
| A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria AK139, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Akeso | 201 | 2026-10-21 | 2026-10-15 |
| Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy CM512, Placebo - Perennial Allergic Rhinitis (PAR) | Phase 2 | Not yet recruiting | Beijing Keymed Biosciences Co., Ltd. | 200 | 2026-10-01 | 2026-10-22 |
| A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis JYP0066 4% topical cream, 3% JYP0066 topical cream, 2% JYP0066 topical cream - Atopic Dermatitis (AD) | Phase 2 | Not yet recruiting | Guangzhou JOYO Pharma Co., Ltd | 160 | 2026-09-30 | 2026-09-30 |
| Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients Epinephrine Nasal Spray, 2.5 mg, Epinephrine Nasal Spray, 5.25 mg - Epinephrine, Hypersensitivity, Immediate | Phase 2 | Not yet recruiting | Hikma Pharmaceuticals USA Inc. | 44 | 2026-09-28 | 2026-10-23 |
| A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria MG-K10 Injection, Matching Placebo - Chronic Urticaria, Idiopathic | Phase 2 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 60 | 2026-09-23 | 2026-09-24 |
| A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs TLL-018 tablets, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 140 | 2026-09-10 | 2026-08-24 |
| A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat Allergy LP-003 Injection - Food Allergy, Wheat Hypersensitivity | Phase 2 | Not yet recruiting | Longbio Pharma (Suzhou) Co., Ltd. | 12 | 2026-09-04 | 2026-09-11 |
| Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis HXN6005, Placebo - Health Adult Subjects, Atopic Dermatitis (AD) | Phase 1 / Phase 2 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 67 | 2026-09-01 | 2026-08-24 |
| Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients LP-003 Injection, Placebo Injection - Peanut Allergies | Phase 2 | Not yet recruiting | Longbio Pharma (Suzhou) Co., Ltd. | 80 | 2026-09-01 | 2026-08-25 |
Showing 20 of 41. Sign in to see all of them.
Dermatitis, Atopic (8) · Asthma (7) · Chronic Urticaria (7) · Sarcoidosis (4) · Sarcoidosis, Pulmonary (3) · Disease (2) · Food Hypersensitivity (2) · Peanut Hypersensitivity (2) · Rhinitis, Allergic, Perennial (2) · Rhinitis, Allergic, Seasonal (2) · Anaphylaxis (1) · Bile Duct Diseases (1) · Biliary Tract Diseases (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1)
Immune System Diseases (41) · Hypersensitivity, Immediate (31) · Skin Diseases (18) · Skin and Connective Tissue Diseases (18) · Respiratory Tract Diseases (16) · Respiratory Hypersensitivity (12) · Lung Diseases (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Dermatitis (10) · Hypersensitivity, Delayed (9) · Chronic Disease (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Disease Attributes (8)
Dehydroepiandrosterone (1) · Ketamine (1) · Levofloxacin (1) · Prednisone (1) · Sirolimus (1) · Sodium Chloride (1) · baricitinib (1) · benralizumab (1) · daratumumab (1) · ginger extract (1) · levocetirizine (1) · upadacitinib (1)
Akeso (4) · Hangzhou Highlightll Pharmaceutical Co., Ltd (3) · Longbio Pharma (Suzhou) Co., Ltd. (2) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Keymed Biosciences Co., Ltd. (1) · Chengdu Kangnuoxing Biopharma,Inc. (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · Copenhagen Respiratory Research (1) · Emily DiMango, MD (1) · Enzychem Lifesciences Corporation (1) · Foresee Pharmaceuticals Co., Ltd. (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Guangzhou JOYO Pharma Co., Ltd (1) · Helixon Biotechnology (Suzhou) Co., Ltd (1) · Hikma Pharmaceuticals USA Inc. (1)
China (16) · United States (5) · France (2) · Argentina (1) · Canada (1) · Oman (1) · Pakistan (1) · Switzerland (1)
Luo Zhang (2) · Bassem Elmankabadi, MD (1) · Chengshuo Wang (1) · Edwin H Kim, MD (1) · Emily DiMango, MD (1) · Jens-Ulrik S. Jensen, Professor, MD, phD (1) · Jianzhong Zhang, Dr (1) · Jianzhong Zhang, MD (1) · Jorge Fernando Maspero, MD, PhD (1) · Kai Guan (1) · Matthew C Baker, MD, MS (1) · Nageshwar Thudi, PhD (1) · Xiong Ma, MD, PhD (1)
2025 (1), P01HL158507 (1), R33AT012627 (1)